2018
DOI: 10.1055/s-0038-1676360
|View full text |Cite
|
Sign up to set email alerts
|

Drug-Eluting Balloons and Drug-Eluting Stents in the Treatment of Peripheral Vascular Disease

Abstract: In the last 20 years, peripheral artery disease (PAD) has been increasingly recognized as a significant cause of morbidity and mortality in the United States. The endovascular treatment of PAD has seen a marked rise as minimally invasive techniques and devices have been refined. Two newer devices, drug-eluting stents and drug-eluting balloons, are on the forefront of the battle against limb loss from PAD. This review focuses on the data backing the use of drug-eluting technologies for use in the peripheral art… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
30
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(31 citation statements)
references
References 80 publications
1
30
0
Order By: Relevance
“…While the routine use of DEB in the femoropopliteal current path is based on a meaningful evidence situation with now 5 multicenter RCT studies from previous years, DES implantation is based on only one signi icantly positive RCT and registry study [34]. The long-term results of the 48-month Zilver PTX study [35,36] with a persistently signi icantly better patency rate than in the BMS group, even in long lesions, must be veri ied by a longer observation period.…”
Section: Discussionmentioning
confidence: 99%
“…While the routine use of DEB in the femoropopliteal current path is based on a meaningful evidence situation with now 5 multicenter RCT studies from previous years, DES implantation is based on only one signi icantly positive RCT and registry study [34]. The long-term results of the 48-month Zilver PTX study [35,36] with a persistently signi icantly better patency rate than in the BMS group, even in long lesions, must be veri ied by a longer observation period.…”
Section: Discussionmentioning
confidence: 99%
“…performing a double contraction with m i ⊗ m i , and remembering that I coll,i 2 , we obtain the following expression for _ l…”
Section: By Projecting Equation (215) Onto the Current Fibre Directionmentioning
confidence: 99%
“…Arterial smooth muscle cells (SMCs) in the media dedifferentiate into their synthetic phenotype, while becoming more proliferative and migratory, causing a significant thickening of the intima, called neointimal hyperplasia [1]. Reported restenosis rates range from less than 5% up to 50% in the first year, depending on the artery treated and the nature of the treatment [2]. The different treatment approaches include percutaneous transluminal angioplasty or the use of bare metal stents, drug-eluting stents or drug-eluting balloons.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…They have been shown to reduce late lumen loss, binary restenosis, and target lesion revascularization (TLR) in the treatment of femoropopliteal disease, compared to conventional angioplasty (5). Majority of DCBs use a paclitaxel-based platform (PCB) and paclitaxel reduces late restenosis by exerting antiproliferative effects to inhibit NIH (6). However, during DCB application, more than 50% of the drug is lost downstream, a phenomenon termed particulate embolization (7).…”
Section: Introductionmentioning
confidence: 99%